Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Elena Garralda(Memorial Sloan Kettering Cancer Center), Rodrigo A. Toledo(Instituto de Salud Carlos III), Charles W. Abbott(Personalis (United States)), Alberto Hernando‐Calvo(Hebron University), Patricia Casbas-Hernández(AstraZeneca (Japan)), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Raquel Pérez-López(Royal Marsden NHS Foundation Trust), José Jimenez(Molecular Oncology (United States)), Neeraja Ravi(Personalis (United States)), Julia Lostes(Hebron University), Ezoglin Oflazoglu(AstraZeneca (Japan)), Elena Élez(Vall d'Hebron Hospital Universitari), Fábio C. P. Navarro(Personalis (United States)), Vladimir Galvao(Hebron University), Ana Belén Moreno-Cárdenas(Vall d'Hebron Hospital Universitari), Francesco Grussu(Hebron University), Roberta Fasani(Vall d'Hebron Institute of Oncology), Belén Ortega(Hebron University), M.Á. Heredero Sanz(Hebron University), Kira Raskina(Hebron University), Eva Muñoz‐Couselo(Hebron University), Rachel Marty Pyke(Personalis (United States)), Richard Chen(Personalis (United States)), A. Oberoi(Hebron University), Oriol Mirallas(Hebron University), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center), Irene Braña(Princess Margaret Cancer Centre), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), G. Alonso(Hebron University), Sean Michael Boyle(Personalis (United States)), Cristina Viaplana(Vall d'Hebron Institute of Oncology), Rodrigo Dienstmann(Cancer Research Center), Kathleen C. Keough(University of North Carolina at Chapel Hill), Carlota Arenillas(Hebron University), Darren Hodgson(AstraZeneca (United Kingdom)), Enriqueta Felip(Universitat Autònoma de Barcelona), Christina Zatse(Hebron University), Bailiang Li(Stanford University), A. Mel Olano(Hebron University), Natalia Czerniak(Hebron University), G. Pretelli(Hebron University), Alma Calahorro(Hebron University), María Vieito(Vall d'Hebron Hospital Universitari)
Cited by 1
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k